Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Melanoma 11/19/2008 - (DGNews)
    TopAbstracts in Melanoma 10/22/2008 - (DGNews)
    Methyl Aminolevulinate Photodynamic Therapy an Alternative to Surgery for Superficial Basal-Cell Carcinoma: Presented at EADV - (DGDispatch)
    TopAbstracts in Melanoma 09/24/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Melanoma

    Webcasts/CME archive

     Recent cases - Melanoma
      A 90-Year-Old Woman with an Asymptomatic Spot on Her Cheek
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      Primary Malignant Melanoma of the Lower Oesophagus Presenting with Dysphagia and Upper Gastrointestinal Bleeding: A Case Report
      Cardiovascular Magnetic Resonance of the Charcoal Heart
      Ring Melanoma of the Ciliary Body: Clinical and Ultrasound Biomicroscopic Characteristics

      Cases archive
        




      my personal edition > melanoma > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Temozolomide Followed By Combined Immunotherapy Aids Metastatic Melanoma

      A DGReview of :"Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNalpha in patients with metastatic melanoma"
      British Journal of Cancer

      03/12/2003
      By Anne MacLennan


      Oral temozolomide (TMZ) followed by subcutaneous combined immunotherapy is effective in patients with metastatic melanoma, researchers in the Netherlands have found.

      Toxicity linked with this treatment is manageable on an outpatient basis, report Dr G C de Gast and colleagues from the Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam.

      They sought to determine both the toxicity and efficacy of oral TMZ followed by subcutaneous (sc) low-dose interleukin-2 (IL2), granulocyte-monocyte colony stimulating factor (GM-CSF) and interferon-alpha 2b (IFN alpha) in these patients. The 74 study participants received, in four separate cohorts, escalating doses of TMZ (150-250 mg m-²) for 5 days followed by sc IL2 (4 MIU m-²), GM-CSF (2.5 microg kg-1) and IFN alpha (5 MIU flat) for 12 days.

      A second identical treatment was scheduled on day 22, and the cycles were repeated in stable or responding patients following evaluation.

      The investigators analysed the data after a median follow-up of 20 months (range: 12 to 30 months).

      Overall, the objective response rate was 31% (23 of 74), with responses occurring in all disease sites, including the central nervous system (CNS).

      Of the 36 patients with responding or stable disease, none developed CNS metastasis as the first or concurrent site of progressive disease.

      Median survival was 252 days (8.3 months), with one year survival of 41%.

      Primary toxicity of TMZ was thrombocytopenia and was dose- and patient-dependent. Lymphocytopenia occurred in 48.5% (34 of 70) of fully monitored patients following TMZ and remained after immunotherapy in two.

      The main toxicity of combined immunotherapy was flu-like syndrome and transient liver function disturbances.
      Br J Cancer 2003 Jan 27;88:2:175-80. "Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNalpha in patients with metastatic melanoma"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send